scholarly journals Pharmacokinetics and biodistribution of a new anti-episialin monoclonal antibody 139H2 in ovarian-cancer-bearing nude mice

1991 ◽  
Vol 34 (3) ◽  
pp. 191-197 ◽  
Author(s):  
Carla F. M. Molthoff ◽  
Herbert M. Pinedo ◽  
Hennie M. M. Schlüper ◽  
Epie Boven
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Nude Mice

scholarly journals Repeated Intraperitoneal -Radioimmunotherapy of Ovarian Cancer in Mice

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Jörgen Elgqvist ◽  
Håkan Andersson ◽  
Holger Jensen ◽  
Helena Kahu ◽  
Sture Lindegren ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Cell Line ◽  
Nude Mice ◽  
Therapeutic Efficacy ◽  
Therapeutic Index ◽  
Repeated Treatment ◽  
Treatment Regimens ◽  
Potential Increase

The aim of this study was to investigate the therapeutic efficacy of -radioimmunotherapy of ovarian cancer in mice using different fractionated treatment regimens. The study was performed using the monoclonal antibody MX35 F labeled with the -particle emitter .Methods. Nude mice were intraperitoneally inoculated with ~ cells of the cell line NIH:OVCAR-3. Four weeks later 6 groups of animals were given F as a single or as a repeated treatment of up to 6 times ( in each group). The fractionated treatments were given every seventh day. Control animals were treated with unlabeled F (). Eight weeks posttreatment the animals were sacrificed and the presence of macro- and microscopic tumors and ascites was determined.Results. The tumor-free fractions (TFFs) of the animals, defined as the fraction of animals with no macro- and microtumors and no ascites, were 0.17, 0.11, 0.39, 0.44, 0.44, and 0.67 when treated with F once or 2, 3, 4, 5, or 6 times, respectively. Repeated treatment 3 times or more resulted in a significantly higher () TFF than compared to treatment once or twice. The presence of ascites decreased from 15 out of 18 animals in the group given only one treatment to zero for the 2 groups given 5 or 6 fractions. Treatment with unlabeled F resulted in a TFF of zero.Conclusion. Weekly repeated intraperitoneal injections of tolerable amounts of activity of F of up to 6 times produced increased therapeutic efficacy without observed toxicity, indicating a potential increase of the therapeutic index.

Therapeutic effect of a radiolabeled monoclonal antibody on human ovarian cancer xenograft in nude mice

1989 ◽  
Vol 32 (3) ◽  
pp. 368-370 ◽  
Author(s):  
Alberto Manetta ◽  
Pondichery G. Satyaswaroop ◽  
Thomas Hamilton ◽  
Robert Ozols ◽  
Rodrigue Mortel
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Therapeutic Effect ◽  
Nude Mice ◽  
Human Ovarian Cancer

Antitumor effect of monoclonal antibody-carboplatin conjugates in nude mice bearing human ovarian cancer cells

1999 ◽  
Vol 4 (4) ◽  
pp. 236-240 ◽  
Author(s):  
Y. Ota ◽  
Ichio Fukasawa ◽  
Hisashi Tokita ◽  
Tomohisa Yamaguchi ◽  
Haruo Yoshino ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Cancer Cells ◽  
Nude Mice ◽  
Antitumor Effect ◽  
Ovarian Cancer Cells ◽  
Human Ovarian Cancer

Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody

1991 ◽  
Vol 27 (6) ◽  
pp. 724-729 ◽  
Author(s):  
F. Crippa ◽  
G.L. Buraggi ◽  
E. Di Re ◽  
M. Gasparini ◽  
E. Seregni ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody

In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice

2006 ◽  
Vol 32 (5) ◽  
pp. 449-453 ◽  
Author(s):  
Pierre Collinet ◽  
Rodolphe Vereecque ◽  
Frédéric Sabban ◽  
Denis Vinatier ◽  
Eric Leblanc ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Gene Transfer ◽  
Antitumor Activity ◽  
Nude Mice ◽  
Plasmid Dna ◽  
Xenograft Model ◽  
P53 Gene ◽  
Naked Plasmid ◽  
Naked Plasmid Dna

LncRNA SNHG14 Promotes Progression of Ovarian Cancer by Regulating miR-206 Expression

2021 ◽  
Vol 7 (5) ◽  
pp. 3997-4004
Author(s):  
Zhibo Zou ◽  
Lin Peng
Keyword(s):  
Ovarian Cancer ◽  
Flow Cytometry ◽  
Cell Proliferation ◽  
Tumor Growth ◽  
Cancer Progression ◽  
Nude Mice ◽  
Luciferase Reporter ◽  
Migration And Invasion ◽  
Qrt Pcr ◽  
Research Objects

Objective: This study aimed to probe into the effect of LncRNA SNHG14 on ovarian cancer progression by regulating miR-206.Methods: Fifty-seven ovarian cancer (OC) patients who were treated in our hospital from December 2017 to December 2019 were collected as the research objects. During the operation, OC tissues and paracancerous tissues of patients were collected, and the effect of SNHG14 on OC tumor growth in nude mice was detected, and SNHG14 inhibitor was transfected into OC cells. The relative expression of SNHG14 in tissues and cells was detected by qRT-PCR, cell proliferation was testedvia CCK8, migration and invasion were detected through Transwell, apoptosis was assessedvia flow cytometry, and the targeted relationship between SNHG14 and miR-206 was detected by dual luciferase reporter gene.Results: SNHG14 is highly expressed in OC tissues, cells and nude mice. Down-regulating it can inhibit the biological ability of OC cells and inhibit the growth of nude mice tumors. It can directly target miR-206 to regulate CCND1 expression and promote OC progression.Conclusion: LncRNA SNHG14 can act as miR-206 sponge to regulate CCND1 expression downstream of miR-206 and promote OC progression.

Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission

2021 ◽  
pp. ijgc-2020-002239
Author(s):  
Oren Smaletz ◽  
Gustavo Ismael ◽  
Maria Del Pilar Estevez-Diz ◽  
Ivana L O Nascimento ◽  
Ana Luiza Gomes de Morais ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Epithelial Ovarian Cancer ◽  
Phase Ii ◽  
Progression Free Survival ◽  
Complete Response ◽  
Free Survival ◽  
Platinum Sensitive ◽  
Platinum Based Chemotherapy ◽  
Lewis Y

ObjectiveTo investigate the efficacy and safety of hu3S193, a humanized anti-Lewis-Y monoclonal antibody, as a consolidation strategy in patients with platinum-sensitive recurrent epithelial ovarian cancer who achieved a second complete response after salvage platinum-doublet chemotherapy.MethodsThis single-arm phase II study accrued patients with recurrent epithelial ovarian cancer with Lewis-Y expression by immunohistochemistry who had achieved a second complete response after five to eight cycles of platinum-based chemotherapy. Patients received intravenous infusions of hu3S193, 30 mg/m2 every 2 weeks starting no more than 8 weeks after the last dose of chemotherapy and continuing for 12 doses, until disease progression, or unacceptable toxicity. The primary endpoint was progression-free survival of the second remission. Secondary objectives were safety and pharmacokinetics.ResultsTwenty-nine patients were enrolled. Most had a papillary/serous histology tumor (94%), stage III disease at diagnosis (75%), and five (17%) underwent secondary cytoreduction before salvage chemotherapy. Two patients were not eligible for efficacy but were considered for toxicity analysis. Eighteen patients (62%) completed the full consolidation treatment while nine patients progressed on treatment. At the time of analysis, 23 patients (85%) of the eligible population had progressed and seven of these patients (26%) had died. Median progression-free survival of the second remission was 12.1 months (95% CI: 10.6–13.9), with a 1-year progression-free survival of the second remission rate of 50.1%. The trial was terminated early since it was unlikely that the primary objective would be achieved. The most commonly reported treatment-related adverse events were nausea (55%) and vomiting (51%).ConclusionsHu3S193 did not show sufficient clinical activity as consolidation therapy in patients with recurrent epithelial ovarian cancer who achieved a second complete response after platinum-based chemotherapy.Trial registrationNCT01137071.

Sign in / Sign up

Export Citation Format

Share Document